Cannabidiol (CBD), a small nonpsychoactive molecule derived from Cannabis sativa, exerts a variety of therapeutic actions, such as anti-inflammatory, antioxidant, and antibacterial. Epidiolex is the only FDA-approved medicine containing pure CBD as an oral solution for seizure-controlling therapy. Nevertheless, the oral bioavailability of CBD is challenging due to its physical-chemical properties such as low solubility in water and high first-pass metabolism. By contrast, inhaled CBD has shown faster absorption and higher plasma concentration. Nanosuspensions represent an optimal strategy to obtain an effective aerosolizable formulation of poorly soluble drugs. In this study, a CBD nanosuspension was produced using a bottom-up technique, namely, a solvent/antisolvent nanoprecipitation. The obtained system was thoroughly characterized in terms of dimensions and ζ potential, nanocrystal morphology, and solid-state properties. The formulation was composed of homogeneously dispersed nanocrystals of approximately 88 nm, with a faster dissolution profile compared with the raw drug and the coarse suspension. The nebulization tests carried out using a Next Generation Impactor (NGI, Apparatus E Ph. Eu) highlighted optimal aerodynamic properties with high values of fine particle fraction and MMAD < 5 μm. Finally, the safety of the nanomedicine was assessed on human pulmonary cells demonstrating excellent biocompatibility.
Design and bottom-up production of an aerosolisable cannabidiol nanosuspension / L. Casula, M. Schlich, M.C. Cardia, E. Lai, S. Marceddu, R. Pireddu, D. Valenti, C. Sinico, F. Lai, E. Pini. - In: MOLECULAR PHARMACEUTICS. - ISSN 1543-8384. - 22:1(2025 Jan 06), pp. 498-508. [10.1021/acs.molpharmaceut.4c01095]
Design and bottom-up production of an aerosolisable cannabidiol nanosuspension
E. PiniUltimo
Conceptualization
2025
Abstract
Cannabidiol (CBD), a small nonpsychoactive molecule derived from Cannabis sativa, exerts a variety of therapeutic actions, such as anti-inflammatory, antioxidant, and antibacterial. Epidiolex is the only FDA-approved medicine containing pure CBD as an oral solution for seizure-controlling therapy. Nevertheless, the oral bioavailability of CBD is challenging due to its physical-chemical properties such as low solubility in water and high first-pass metabolism. By contrast, inhaled CBD has shown faster absorption and higher plasma concentration. Nanosuspensions represent an optimal strategy to obtain an effective aerosolizable formulation of poorly soluble drugs. In this study, a CBD nanosuspension was produced using a bottom-up technique, namely, a solvent/antisolvent nanoprecipitation. The obtained system was thoroughly characterized in terms of dimensions and ζ potential, nanocrystal morphology, and solid-state properties. The formulation was composed of homogeneously dispersed nanocrystals of approximately 88 nm, with a faster dissolution profile compared with the raw drug and the coarse suspension. The nebulization tests carried out using a Next Generation Impactor (NGI, Apparatus E Ph. Eu) highlighted optimal aerodynamic properties with high values of fine particle fraction and MMAD < 5 μm. Finally, the safety of the nanomedicine was assessed on human pulmonary cells demonstrating excellent biocompatibility.File | Dimensione | Formato | |
---|---|---|---|
casula-et-al-2024-design-and-bottom-up-production-of-an-aerosolizable-cannabidiol-nanosuspension.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
6.2 MB
Formato
Adobe PDF
|
6.2 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
mp-2024-01095q_Proof_hi.pdf
embargo fino al 06/01/2026
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
1.06 MB
Formato
Adobe PDF
|
1.06 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.